Daphnetin Alleviates Bleomycin-Induced Pulmonary Fibrosis through Inhibition of Epithelial-to-Mesenchymal Transition and IL-17A
Soo-Jin Park, Hyung Won Ryu, Ji-Hyeong Kim, Hwa-Jeong Hahn, Hyun-Jae Jang, Sung-Kyun Ko, Sei-Ryang Oh, Hyun-Jun Lee, Christoffel Arnold Spek · 2023
Read Daphnetin Alleviates Bleomycin-Induced Pulmonary Fibrosis through Inhibition of Epithelial-to-Mesenchymal Transition and IL-17A by Soo-Jin Park, Hyung Won Ryu, Ji-Hyeong Kim, Hwa-Jeong Hahn, Hyun-Jae Jang, Sung-Kyun Ko, Sei-Ryang Oh, Hyun-Jun Lee, Christoffel Arnold Spek (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10742308.txt.
Description
Soo-Jin Park and co-authors test daphnetin, a natural plant compound, as a treatment for scarred lungs in a 2023 study. The disease they target, idiopathic pulmonary fibrosis, stiffens the lungs and has no cure.
The team studied immune cells in dishes, human lung cells, and mice given a drug that scars the lungs. Daphnetin cut production of IL-17A, a signal made by a class of immune cells. It also blocked a harmful change in lung cells driven by a growth signal. Mice fed the compound by mouth showed less lung damage and better lung function. The authors suggest the compound could become a drug candidate, since it acts on both the immune side and the scarring side of the disease.
Catalog record
| CREATOR | Soo-Jin Park, Hyung Won Ryu, Ji-Hyeong Kim, Hwa-Jeong Hahn, Hyun-Jae Jang, Sung-Kyun Ko, Sei-Ryang Oh, Hyun-Jun Lee, Christoffel Arnold Spek |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |